Comparative assessment of calcitonin stimulation test using calcium gluconate and pentagastrin and the usefulness of procalcitonin basic and post-stimulation concentrations in the diagnosis of patients after surgery for medullary.
OBJECTIVE
The aim of the study was to compare the calcitonin (CT) stimulation tests with tests of calcium gluconate (CaG) and pentagastrin (PG), their tolerance and usefulness of PCT in the patients' diagnosis with active Medullary thyroid cancer (MCT) after thyroidectomy.


METHODS
CT was marked in serum by the immunosorbent sandwich test. PCT was marked by the immunosorbent sandwich test, with the final reading of fluorenscence. PG was given intravenously at a dose of 0.5 mg/kg body weight for 10 seconds. CaG was also given by intravenous injection at a dose of 2.5 mg of elemental Ca/kg body weight at a rate of 5ml/min, for minimum 3 minutes. Blood was taken at the 0 minute, the 3 and 5 minute after getting the stimulating substances.


RESULTS
The post-stimulation CT concentration in the 3 and 5 minute of the CaG test vs PG is significantly higher compared to the baseline. The maximal stimulation of the CT is in the 3 minute, but higher concentrations occurred using the CaG.


CONCLUSIONS
The results of the study suggest a similar diagnostic value of the tests with CaG compared to the PG as stimulants. In the present study we noticed a trend of basic and post-stimulation concentrations of PCT to increase in the tests with PG and CaG which correspond with the elevated concentrations of CT.
Holycross Cancer Center, Department of Endocrinology in Kielce, Poland.
Aldona
A
Kowalska
Holycross Cancer Center, Department of Endocrinology in Kielce, Poland.
Katarzyna
K
Lizis-Kolus
Holycross Cancer Center, Department of Endocrinology in Kielce, Poland.
Danuta
D
Gąsior-Perczak
Holycross Cancer Center, Department of Endocrinology in Kielce, Poland.
Iwona
I
Palyga
Holycross Cancer Center, Department of Tumor Markers in Kielce, Poland.
Anna
A
Słuszniak
Holycross Cancer Center, Department of Surgical Oncology in Kielce, Poland.
Janusz
J
Słuszniak
Holycross Cancer Center, Department of Laboratory Diagnostics in Kielce, Poland.
Grażyna
G
Antczak
Holycross College, Department of Physiotherapy in Kielce, Poland.
Paweł
P
Lizis
Holycross Cancer Center, Department of Endocrinology in Kielce, Poland.
Ryszard
R
Mezyk
Holycross Cancer Center, Department of Chemotherapy in Kielce, Poland.
Stanislaw
S
Gozdz
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002116:Calcitonin / Q000097:blood*; D002125:Calcium Gluconate / Q000494:pharmacology*; D018276:Carcinoma, Medullary / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin / Q000008:administration & dosage / Q000494:pharmacology*; D013961:Thyroid Gland / Q000601:surgery; D013964:Thyroid Neoplasms / Q000601:surgery; D013965:Thyroidectomy / Q000379:methods
D014408:Biomarkers, Tumor; D002116:Calcitonin; D010418:Pentagastrin; D002125:Calcium Gluconate